|
| << vorige | volgende >> |
Tijdschrift beschrijving
Alle jaargangen van het bijbehorende tijdschrift
Alle afleveringen van het bijbehorende jaargang
Alle artikelen van de bijbehorende aflevering
Details van artikel 3 van 5 gevonden artikelen
| Titel: |
Pharmacokinetic Profiles of Two Branded Formulations of Piroxicam 20mg in Healthy Korean Volunteers by a Rapid Isocratic HPLC Method |
| Auteur: |
Hyun Ho Song Kwang Sik Choi Chan-Wha Kim Young Ee Kwon |
| Verschenen in: |
Journal of bioequivalence & bioavailability |
| Paginering: | Jaargang 01 (2009) nr. 03 pagina's 074-079 |
| Jaar: |
2009 |
| Inhoud: |
The aim of this study was to develop and validate fordetermination of piroxicam in human plasma by newrapid HPLC method and to compare the relativebioavailability of two branded formulations of piroxicamin healthy Korean volunteers. The analysis running timeof piroxicam was just 2 minutes using C18 column (100 x4.6 mm, 5 μm) with variable wavelength detector (at 355nm). This HPLC method was validated by examiningthe precision and accuracy for inter- and intra-day analysis.A randomized, open-label, single dose, 2-period crossover method was performed in 28 subjects. For analysis of pharmacokinetic properties, the blood samples were drawn at 0, 1, 2, 3, 4, 5, 6, 12, 24, 48, 96 and 168 hours after dosing. The standard curve was linear (R2 = 0.9999) over the concentration range of 0.1 - 6 μg/mL. The relative standard deviation (R.S.D.) and accuracy were 0.2 - 6.1 % and 95.4 - 104.0 %. After single dose of piroxicam 20 mg, the plasma pharmacokinetic parameters, Cmax, Tmax,t1/2 and AUCt were 2.15 ± 0.25 μg/mL, 2.44 ± 1.15 h,46.84 ± 8.73 h and 107.42 ± 27.25 μg·h/mL in the test drug. No significant differences were found based on analysis of variance, with mean values and 90% CIs of test/reference ratio for these parameters as follows: Cmax was 0.9351-1.0377; AUC0-168 was 0.9510-1.0752. The developed method was successfully applied to bioequivalence study of two branded piroxicam capsules in 28 healthy Korean. The results of pharmacokinetics showed two branded piroxicam 20 mg formulations were bioequivalent, based on the regulatory definition. |
| Uitgever: |
OMICS Publishing Group (provided by DOAJ) |
| Bronbestand: |
Elektronische Wetenschappelijke Tijdschriften |
Details van artikel 3 van 5 gevonden artikelen
| << vorige | volgende >> |